|
The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 75 formulations under Drugs Prices Control Order (DPCO) -2013 based on 70th Authority meeting held on October 30, 2019.
Name of the formulations include emtricitabine + tenofovir tablet (Tafmune – EM), emtricitabine + tenofovir alafenamide tablet, tenofovir alafenamide tablet, tenofovir + emtricitabine tablet (Taficita), tenofovir alafenamide tablet (Tenocruz AF), cetaminophen (paracetamol) + tramadol hydrochloride tablets, amoxycillin + potassium clavulanate suspension, glimepiride + metformine tablet (Gluformin G 0.5), emtricitabine + tenofovir alafenamide tablet, cefixime + potassium clavulanate suspension, calcium carbonate + vitamin d3+ mecobalamin + l-methylfolate + pyridoxal – 5-phosphate tablet, budesonide capsule, diclofenac diethylamine + methyl salicylate + menthol + absolute alcohol spray, dolutegravir + lamivudine + tenofovir disoproxil tablet and telmisartan + metoprolol tablet.
All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price as specified plus goods and services taxes applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO 2013. The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price specified.
The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to state drug controller and dealers.
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
The manufacturers not complying with the ceiling price and notes specified herein above shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities (EC) Act, 1955.
Consequent to the issue of ceiling prices of such formulations as specified in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the said date of notification, stand(s) superseded, the NPPA in its notification said.
|